Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsMIL:1QDX 54 Return-on-Tangible-Asset is 21.39% as of Jun. 2026, which is 4% above its 10-year median of 20.66. GuruFocus rates MIL:1QDX with a GF Score™ of 54/100 and a GF Value™ of €159.37 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Quest Diagnostics ranks better than 91.51% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Quest Diagnostics's annualizedNet Income for the quarter that ended in Jun. 2026 was €1,111 Mil. Quest Diagnostics's average total tangible assets for the quarter that ended in Jun. 2026 was €5,195 Mil. Therefore, Quest Diagnostics's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 21.39%.
The historical rank and industry rank for Quest Diagnostics's Return-on-Tangible-Asset or its related term are showing as below:
MIL:1QDX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 16.35 Med: 20.66 Max: 35.2
Current: 18.53
During the past 13 years, Quest Diagnostics's highest Return-on-Tangible-Asset was 35.20%. The lowest was 16.35%. And the median was 20.66%.
MIL:1QDX's Return-on-Tangible-Asset is ranked better than 91.51% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.325
vs MIL:1QDX: 18.53
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Quest Diagnostics Return-on-Tangible-Asset Related Terms
Quest Diagnostics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1QDX vs LH, MTD, ILMN: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Quest Diagnostics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 21.39% mean?
Quest Diagnostics (MIL:1QDX) has a Return-on-Tangible-Asset of 21.39% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Quest Diagnostics and its competitors. This is near median its historical median of 20.66. Over the past decade, Quest Diagnostics' Return-on-Tangible-Asset has ranged from 16.35 to 35.20. According to the industry distribution chart, Quest Diagnostics ranks #18 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 8.5%.
Is Quest Diagnostics' Return-on-Tangible-Asset too high?
Quest Diagnostics' current Return-on-Tangible-Asset of 21.39% is near median its 10-year median of 20.66. Over the past 10 years, this metric has ranged from a low of 16.35 to a high of 35.20. Based on the distribution chart, Quest Diagnostics ranks #18 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Quest Diagnostics has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Return-on-Tangible-Asset compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #18 out of 212 companies for Return-on-Tangible-Asset. This places Quest Diagnostics in the top 9% of its industry — outperforming the majority of peers. Historically, Quest Diagnostics' own Return-on-Tangible-Asset has ranged from 16.35 to 35.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current Return-on-Tangible-Asset is 21.39%, which is near median its own 10-year median of 20.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (MIL:1QDX) is currently considered Modestly Overvalued. The stock's GF Value™ is €159.37, compared to a current price of €206.90 — trading 29.8% above its estimated fair value. The current Return-on-Tangible-Asset is 21.39%, which is near median its 10-year median of 20.66. Quest Diagnostics' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Quest Diagnostics (MIL:1QDX), the current Return-on-Tangible-Asset is 21.39% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (MIL:1QDX) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €206.90 is trading 29.8% above its estimated GF Value™ of €159.37.
GuruFocus considers Quest Diagnostics to be Modestly Overvalued.
Key valuation signals for MIL:1QDX:
Return-on-Tangible-Asset: 21.39% (near median its 10-year median of 20.66)
GF Value™: €159.37 vs. price of €206.90 (29.8% above fair value)
No single metric tells the full story. See the MIL:1QDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
54GF Score
Get the complete analysis for MIL:1QDX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1QDX has been successfully added to your 
